Immuno-Oncology Executive, Physician, and Scientist with 20 years of experience, including 15 years of Clinical and Corporate Development and Commercial Experience in Biotech and Biopharma and 5 years in Medicine, including key clinical and business operations at Iovance Biotherapeutics, VBL Therapeutics, Bristol Myers Squibb, Goldman Sachs, and the National Cancer Institute of the NIH. Blending medicine and business with a proven track record in immuno-oncology drug development, commercialization and launches, medical strategy, marketing, M&A, and operations. At Iovance, improved cell therapy operations, expanded and executed late-stage clinical program, designing and running clinical trials, and launch readiness. As US Chief Operating Officer at VBL Therapeutics helped lead clinical development, commercial planning and delivered transformative financial results. Launch Lead for OPDIVO in multiple indications at BMS, led multibillion-dollar global transactions, negotiations, M&A and partnerships.